- Autorzy:
-
Smith, William B.
Zhi, Yuxiang
Bara, Noémi-Anna
Aberer, Werner
Peter, Jonathan
Longhurst, Hilary
Zuraw, Bruce
Magerl, Markus
Nguyen, Dinh
Ansotegui, Ignacio J.
Banerji, Aleena
Gower, Richard
Farkas, Henriette
Gompels, Mark
Cohn, Danny M.
Boccon-Gibod, Isabelle
Pawankar, Ruby
Kiani-Alikhan, Sorena
Bork, Konrad
Martinez Saguer, Inmaculada
Sheikh, Farrukh Rafique
Stobiecki, Marcin
Varga, Lilian Agnes
Bouillet, Laurence
Macginnitie, Andrew
Nieto-Martinez, Sandra A.
Toubi, Elias
Lumry, William
Aygören-Pürsün, Emel
Kang, Hye-Ryun
Katelaris, Constance H.
Prior, Nieves
Riedl, Marc
Maurer, Marcus
Zanichelli, Andrea
Malbran, Alejandro
Spaeth, Peter J
Porębski, Grzegorz
Nast, Alexander
Ritchie, Bruce
Matta Campos, Juan José
Lei, Wei-Te
Busse, Paula J.
Bygum, Anette
Brodszki, Nicholas
Cancian, Mauro
Kaplan, Allen P.
Lockey, Richard F.
Hide, Michihiro
Reshef, Avner
Weller, Karsten
Craig, Timothy
Caballero, Teresa
Boysen, Henrik Balle
Castaldo, Anthony J.
Csuka, Dorottya
Grumach, Anete S.
Betschel, Stephen
Guidos-Fogelbach, Guillermo - Opis:
- Hereditary Angioedema (HAE) is a rare and disabling disease for which early diagnosis and effective therapy are critical. This revision and update of the global WAO/EAACI guideline on the diagnosis and management of HAE provides up-to-date guidance for the management of HAE. For this update and revision of the guideline, an international panel of experts reviewed the existing evidence, developed 28 recommendations, and established consensus by an online DELPHI process. The goal of these recommendations and guideline is to help physicians and their patients in making rational decisions in the management of HAE with deficient C1-inhibitor (type 1) and HAE with dysfunctional C1-inhibitor (type 2), by providing guidance on common and important clinical issues, such as: 1) How should HAE be diagnosed? 2) When should HAE patients receive prophylactic on top of on-demand treatment and what treatments should be used? 3) What are the goals of treatment? 4) Should HAE management be different for special HAE patient groups such as children or pregnant/breast feeding women? 5) How should HAE patients monitor their disease activity, impact, and control? It is also the intention of this guideline to help establish global standards for the management of HAE and to encourage and facilitate the use of recommended diagnostics and therapies for all patients.
- Dostawca treści:
- Repozytorium Uniwersytetu Jagiellońskiego
Artykuł